The price of NovoCure Ltd (NASDAQ: NVCR) closed at $12.72 in the last session, down -6.26% from day before closing price of $13.57. On the day, 1120129 shares were traded.
Ratios:
We take a closer look at NVCR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.56 and its Current Ratio is at 5.78. In the meantime, Its Debt-to-Equity ratio is 1.67 whereas as Long-Term Debt/Eq ratio is at 1.64.
On August 28, 2023, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $85 to $25.
Piper Sandler Upgraded its Neutral to Overweight on August 08, 2023, while the target price for the stock was maintained at $45.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 04 ’24 when GROENHUYSEN WILHELMUS CM sold 1,217 shares for $16.01 per share. The transaction valued at 19,484 led to the insider holds 251,235 shares of the business.
Leonard Frank X sold 840 shares of NVCR for $13,448 on Mar 04 ’24. The EVP, Pres., Novocure Oncology now owns 160,098 shares after completing the transaction at $16.01 per share. On Mar 01 ’24, another insider, GROENHUYSEN WILHELMUS CM, who serves as the Chief Operating Officer of the company, sold 2,107 shares for $16.03 each. As a result, the insider received 33,769 and left with 252,452 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.67 while its Price-to-Book (P/B) ratio in mrq is 3.76.
Stock Price History:
Over the past 52 weeks, NVCR has reached a high of $83.60, while it has fallen to a 52-week low of $10.87.
Shares Statistics:
A total of 107.08M shares are outstanding, with a floating share count of 96.28M. Insiders hold about 10.09% of the company’s shares, while institutions hold 84.68% stake in the company.
Earnings Estimates
The company has NovoCure Limited analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $7,761.44, with high estimates of $299.54 and low estimates of $6.41.
EPS for the following year is $Stocks, with Stocks analysts recommending between $ETF and $Stocks.
